Derleme
BibTex RIS Kaynak Göster

IL-17/TNF-α BISPECIFIC ANTIBODIES AS NEW THERAPEUTIC APPROACH TO RHEUMATOID ARTHRITIS

Yıl 2020, Cilt: 7 Sayı: 1, 37 - 40, 29.02.2020

Öz

Rheumatoid arthritis is a systemic autoimmune disease characterized by chronic inflammation causing swelling in the joints. IL17/TNF-α bispecific antibodies are antibodies that can bind to two different types of epitopes and work on two different types of
receptors. IL-17/TNF-α bispecific antibodies have anti-inflammatory effects that act by blocking the inflammatory pathways of
rheumatoid arthritis. Thus, bispecific antibodies have the potential to be the latest effective therapy against rheumatoid arthritis.
Keywords: Bispecific antibodies, rheumatoid arthritis, therapeutics

Kaynakça

  • 1. Sridhar R, Ramya SS, Sowjanya S. Rheumatoid arthritis - a review. World J Pharm Pharm Sci 2016;5(10):1283–302. 2. Xu B, Lin J. Characteristics and risk factors of rheumatoid arthritis in the United States: An NHANES analysis. PeerJ 2017;24(5). 3. Mcinnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365(23):2205–19. 4. Cooles FA, Isaacs JD. Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol 2011;23(3):233–40. 5. Miura Y, Ota S, Peterlin M et al. Subpopulation of synovial fibroblasts leads to osteochondrogenesis in a mouse model of chronic inflammatory rheumatoid arthritis. JBMR Plus 2018;3(6):1–10. 6. Mellado M, Martinz-Munoz L, Cascio G et al. T cell migration in rheumatoid arthritis. Front Immunol 2015;6:384. 7. Bustamante MF, Garcia-Carbonell R, Whisenant KD et al. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 2017;19(110):1–12. 8. Xu L, Zhang Y, Wang Q et al. Bi-specific antibodies with high antigen-binding affinity identified by flow cytometry. Int Immunopharmacol 2015;24(2):463–73. 9. Byrne H, Conroy PJ, Whisstock JC et al. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013;31(11):621-32. 10. Taylor P, Kontermann RE. Dual targeting strategies with bispecific antibodies. mAbs 2012;4(2):182-97. 11. Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015;67(2):95–106. 12. Chon JH, Zarbis-Papastoitsis G. Advances in the production and downstream processing of antibodies. N Biotechnol 2011;28(5):458– 63. 13. Klein C, Schaefer W, Regula JT et al. Engineering therapeutic bispecific antibodies using CrossMab technology. Methods 2019;154:21–31. 14. Michal P, Timo R, Wagne IL et al. FcRn: the architect behind the immune and non-immune functions of IgG and albumin. J Immunol 2015;194(10):4595–603. 15. Levin D, Golding B, Strome SE et al. Fc fusion as a platform technology: potential for modulating immunogenicity. Trends Biotechnol 2015;33(1):27–34. 16. Sedykh SE, Prinz VV, Buneva VN et al. Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther 2018;12:195–208. 17. Xu T, Ying T, Wang L et al. A native-like bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factor-alpha and interleukin-17A. Oncotarget 2017;8(47):81860–72. 18. Noack M, Beringer A, Miossec P. Additive or synergistic interactions between IL-17A or IL-17F and TNF or IL-1β depend on the cell type. Front Immunol 2019;10:1–12. 19. Yoshitomi H. Regulation of immune responses and chronic inflammation by fibroblast-like synoviocytes. Front Immunol 2019;10:1–8. 20. Liu Z, Song L, Wang Y et al. A novel fusion protein attenuates collagen – induced arthritis by targeting interleukin 17A and tumor necrosis factor α. Int J Pharm 2018;547(1– 2):72–82. 21. Fischer J, Hueber A, Wilson S et al. Combined inhibition of TNFα and IL-17 as therapeutic opportunity for treatment in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol 2015;67(1):51–62. 22. Alzabin S, Abraham SM, Taher TE et al. Incomplete response of inflammatory arthritis to TNF-α blockade is associated with the Th17 pathway. Ann Rheum Dis 2012;71(10):1741–8.
Yıl 2020, Cilt: 7 Sayı: 1, 37 - 40, 29.02.2020

Öz

Kaynakça

  • 1. Sridhar R, Ramya SS, Sowjanya S. Rheumatoid arthritis - a review. World J Pharm Pharm Sci 2016;5(10):1283–302. 2. Xu B, Lin J. Characteristics and risk factors of rheumatoid arthritis in the United States: An NHANES analysis. PeerJ 2017;24(5). 3. Mcinnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365(23):2205–19. 4. Cooles FA, Isaacs JD. Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol 2011;23(3):233–40. 5. Miura Y, Ota S, Peterlin M et al. Subpopulation of synovial fibroblasts leads to osteochondrogenesis in a mouse model of chronic inflammatory rheumatoid arthritis. JBMR Plus 2018;3(6):1–10. 6. Mellado M, Martinz-Munoz L, Cascio G et al. T cell migration in rheumatoid arthritis. Front Immunol 2015;6:384. 7. Bustamante MF, Garcia-Carbonell R, Whisenant KD et al. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 2017;19(110):1–12. 8. Xu L, Zhang Y, Wang Q et al. Bi-specific antibodies with high antigen-binding affinity identified by flow cytometry. Int Immunopharmacol 2015;24(2):463–73. 9. Byrne H, Conroy PJ, Whisstock JC et al. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013;31(11):621-32. 10. Taylor P, Kontermann RE. Dual targeting strategies with bispecific antibodies. mAbs 2012;4(2):182-97. 11. Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015;67(2):95–106. 12. Chon JH, Zarbis-Papastoitsis G. Advances in the production and downstream processing of antibodies. N Biotechnol 2011;28(5):458– 63. 13. Klein C, Schaefer W, Regula JT et al. Engineering therapeutic bispecific antibodies using CrossMab technology. Methods 2019;154:21–31. 14. Michal P, Timo R, Wagne IL et al. FcRn: the architect behind the immune and non-immune functions of IgG and albumin. J Immunol 2015;194(10):4595–603. 15. Levin D, Golding B, Strome SE et al. Fc fusion as a platform technology: potential for modulating immunogenicity. Trends Biotechnol 2015;33(1):27–34. 16. Sedykh SE, Prinz VV, Buneva VN et al. Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther 2018;12:195–208. 17. Xu T, Ying T, Wang L et al. A native-like bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factor-alpha and interleukin-17A. Oncotarget 2017;8(47):81860–72. 18. Noack M, Beringer A, Miossec P. Additive or synergistic interactions between IL-17A or IL-17F and TNF or IL-1β depend on the cell type. Front Immunol 2019;10:1–12. 19. Yoshitomi H. Regulation of immune responses and chronic inflammation by fibroblast-like synoviocytes. Front Immunol 2019;10:1–8. 20. Liu Z, Song L, Wang Y et al. A novel fusion protein attenuates collagen – induced arthritis by targeting interleukin 17A and tumor necrosis factor α. Int J Pharm 2018;547(1– 2):72–82. 21. Fischer J, Hueber A, Wilson S et al. Combined inhibition of TNFα and IL-17 as therapeutic opportunity for treatment in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol 2015;67(1):51–62. 22. Alzabin S, Abraham SM, Taher TE et al. Incomplete response of inflammatory arthritis to TNF-α blockade is associated with the Th17 pathway. Ann Rheum Dis 2012;71(10):1741–8.
Toplam 1 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Klinik Tıp Bilimleri
Bölüm Derleme
Yazarlar

Muhammad Luthfi Adnan Bu kişi benim

Yayımlanma Tarihi 29 Şubat 2020
Gönderilme Tarihi 14 Mayıs 2019
Yayımlandığı Sayı Yıl 2020 Cilt: 7 Sayı: 1

Kaynak Göster

APA Adnan, M. L. (2020). IL-17/TNF-α BISPECIFIC ANTIBODIES AS NEW THERAPEUTIC APPROACH TO RHEUMATOID ARTHRITIS. Turkish Medical Student Journal, 7(1), 37-40.
AMA Adnan ML. IL-17/TNF-α BISPECIFIC ANTIBODIES AS NEW THERAPEUTIC APPROACH TO RHEUMATOID ARTHRITIS. TMSJ. Şubat 2020;7(1):37-40.
Chicago Adnan, Muhammad Luthfi. “IL-17/TNF-α BISPECIFIC ANTIBODIES AS NEW THERAPEUTIC APPROACH TO RHEUMATOID ARTHRITIS”. Turkish Medical Student Journal 7, sy. 1 (Şubat 2020): 37-40.
EndNote Adnan ML (01 Şubat 2020) IL-17/TNF-α BISPECIFIC ANTIBODIES AS NEW THERAPEUTIC APPROACH TO RHEUMATOID ARTHRITIS. Turkish Medical Student Journal 7 1 37–40.
IEEE M. L. Adnan, “IL-17/TNF-α BISPECIFIC ANTIBODIES AS NEW THERAPEUTIC APPROACH TO RHEUMATOID ARTHRITIS”, TMSJ, c. 7, sy. 1, ss. 37–40, 2020.
ISNAD Adnan, Muhammad Luthfi. “IL-17/TNF-α BISPECIFIC ANTIBODIES AS NEW THERAPEUTIC APPROACH TO RHEUMATOID ARTHRITIS”. Turkish Medical Student Journal 7/1 (Şubat 2020), 37-40.
JAMA Adnan ML. IL-17/TNF-α BISPECIFIC ANTIBODIES AS NEW THERAPEUTIC APPROACH TO RHEUMATOID ARTHRITIS. TMSJ. 2020;7:37–40.
MLA Adnan, Muhammad Luthfi. “IL-17/TNF-α BISPECIFIC ANTIBODIES AS NEW THERAPEUTIC APPROACH TO RHEUMATOID ARTHRITIS”. Turkish Medical Student Journal, c. 7, sy. 1, 2020, ss. 37-40.
Vancouver Adnan ML. IL-17/TNF-α BISPECIFIC ANTIBODIES AS NEW THERAPEUTIC APPROACH TO RHEUMATOID ARTHRITIS. TMSJ. 2020;7(1):37-40.